162 related articles for article (PubMed ID: 11408207)
1. In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates.
Zaoutis T; Moore LS; Furness K; Klein JD
Antimicrob Agents Chemother; 2001 Jul; 45(7):1952-4. PubMed ID: 11408207
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
5. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
7. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
[TBL] [Abstract][Full Text] [Related]
9. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Raad II; Hanna HA; Hachem RY; Dvorak T; Arbuckle RB; Chaiban G; Rice LB
Antimicrob Agents Chemother; 2004 Sep; 48(9):3583-5. PubMed ID: 15328133
[TBL] [Abstract][Full Text] [Related]
10. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.
Betriu C; Redondo M; Palau ML; Sánchez A; Gómez M; Culebras E; Boloix A; Picazo JJ
Antimicrob Agents Chemother; 2000 Jul; 44(7):1838-41. PubMed ID: 10858339
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.
John MA; Pletch C; Hussain Z
J Antimicrob Chemother; 2002 Dec; 50(6):933-8. PubMed ID: 12461014
[TBL] [Abstract][Full Text] [Related]
17. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Cha R; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
[TBL] [Abstract][Full Text] [Related]
19. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of viridans group streptococci.
Tuohy M; Washington JA
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):277-80. PubMed ID: 9458986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
